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whether the same can be said of the efforts required to
convince bureaucrats and agencies to fund longitudinal,
observational research of the scope that will be needed
to show the long term benefits of breast feeding—but I
would welcome the opportunity to stand corrected.
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Intrauterine factors, adiposity, and hyperinsulinaemia
Thin babies with excess body fat may explain later adiposity in Indians
The first world congress on fetal origins of adultdisease was held in Mumbai, India, in 2001. Thesecond congress was recently held in Brighton,
United Kingdom. In spite of their diverse locations both
these meetings were dominated by data from developed
countries. This is largely a consequence of the extreme
rarity of good historical records of birth size from devel-
oping countries. The recent insights emerging from
prospective studies by Yajnik et al in Pune in India are
therefore notable and deserve attention.1 2
The core of the theory of fetal origins of disease is
that nutritional deprivation of the fetus during critical
periods of development forces the baby to resort to
adaptive survival strategies, which entail a resetting of
the normal course of metabolic, physiological, and ana-
tomical development. These adaptations become mala-
daptive if the organism encounters contrasting nutri-
tional circumstances in later life. In relation to insulin
action and diabetes Hales and Barker have described
this phenomenon as the “thrifty phenotype.”3 In the
words of J V Neel, the initial proponent of the thrifty
genotype hypothesis,4 the thrifty phenotype is “rendered
detrimental by progress” and leads to high rates of
metabolic syndrome and type 2 diabetes.5 Recently it has
become apparent that it is the disharmony between fetal
growth and later growth rates that seems to be the best
predictor of the later pathology.6 7
A wide range of pathological and non-pathological
factors influence fetal growth. Some of these are modifi-
able during pregnancy (smoking, alcohol, intake of
nutrients), and others are essentially fixed at the
moment of conception. One of these fixed influences is
a mother’s body size and composition. In the Indian
studies pregnant women are very small.1 In rural villages
they average about 44 kg in mid-gestation, with a height
of 1.52 metres and body mass index of 18 kg/m2. Under
such circumstances maternal uterine constraint
becomes a dominant regulator of fetal growth in order
to protect the mother from having to deliver an
inappropriately large baby. The importance of uterine
constraint has been known for many decades and was
graphically shown by Walton and Hammond in their
experiments crossing shire horse sires with Shetland
ponymares thatweremuch smaller.Theuterine environ-
ment in the mare suppressed the inherited growth
potential of the paternal chromosomes and produced
appropriately small foals to allow natural delivery.8 More
recently the molecular biology of this process is emerg-
ing as a fascinating conflict between maternal and pater-
nal influences that involves a range of imprinted genes,
especially insulin-like growth factor-2 and its receptors.9
The details aside it has become clear that maternal con-
straint must have a central role in fetal programming.
Together with Caroline Fall from David Barker’s
Medical Research Council group in Southampton,
Yajnik and his team have used anthropometric
measurements of babies to describe their morphology at
birth. The picture that emerges is of Indian babies that
are much smaller than those in Southampton in all
respects except measures of body fat—especially central
fat as judged by the subscapular skinfold thickness.1 2
They describe this as the “thin-fat” baby syndrome and
believe that it shows that the excess visceral adiposity of
most Asian adults can be traced back to the neonate.
In collaboration with Yudkin at University College
London Yajnik has shown that in the babies of urban
mothers in Pune, insulin concentrations in the blood of
the cord seem raised compared with the British babies
and are correlated with subscapular skinfold thickness.2
Later in childhood these thin-fat Indian babies can be
shown to have profoundly impaired indices of insulin
sensitivity, which are inversely correlated with birth
weight.10 11 These correlations with birth weight are
importantly modified by both their postnatal growth
rate and their achieved size in relation to their predicted
size based on mid-parental height; with greater growth
equating to worse insulin resistance (data presented by
Yajnik at the recent Brighton congress). These findings
emphasise the issues about disharmonious growth
being a major contributor to later pathology.
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Much controversy remains about whether the
diabetogenic inheritance of being small at birth is
mediated through effects on insulin resistance or
secretion, or both. The Indian group surmise that it is
the extra adipose tissue mass that is driving insulin
resistance, probably through its action as a quasi-
endocrine organ,12 but this remains to be proved.
The fetal origins theory is of greatest relevance to
the developing world, and the implications of this work
for global health are enormous. Around 95% of the
world’s growth retarded babies are born in developing
countries, and a recent report from the World Health
Organization and United Nations Food and Agriculture
Organization (FAO) predicted that a global epidemic of
obesity driven type 2 diabetes will soon dominate health
care for chronic diseases, especially in Asia.13
So how should we try to intervene to limit the dam-
age? The obvious response to the “small baby predicts
later disease” paradigm is to propose dietary
supplementation of mothers to produce larger babies.
To a certain extent this seems sensible; we should
probably act to prevent retarded fetal growth in
mothers whose diet is so poor as to limit the baby’s
expected growth trajectory in relation to its parental
and genetic inheritance, and to the maternal uterine
environment. However, the picture is worryingly
confounded by the issue of intergenerational maternal
constraint. If we already have short thin-fat mothers
producing small thin-fat babies, should we really be
feeding them more? Possibly not if this results in aug-
mented fetal growth which will be out of harmony with
the baby’s inheritance and future growth patterns. The
resolution of this conundrum will require focused
investment in international studies on the regulation of
early human growth and development.
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Herbal medicines put into context
Their use entails risks, but probably fewer than with synthetic drugs
Recent reviews have rightly alerted us to the riskassociated with herbal medicines.1 This isnecessary and important. But the more impor-
tant question probably is—do the risks of herbal
benefits outweigh their potential for harm? Therefore I
will try to put herbal medicines into context and
consider the benefit they might bring.
The potential benefits of herbal medicines could lie
in their high acceptance by patients, efficacy, relative
safety, and relatively low costs. Patients worldwide seem
to have adopted herbal medicines in a major way. Sur-
vey data from the United Kingdom show that herbal
medicine has been tried by about 30% of the British
population.2 The associated out of pocket expenditure
was estimated to amount to £31m (US$47.7m; €45m)
in the United Kingdom2 and £1.3bn in Germany.3
Herbal medicines are used predominantly for minor
and self limiting indications, with respiratory tract
infections heading the list.3 But even for those
conditions the remarkable acceptance of herbal medi-
cines can be a good thing only if they can be shown to
do more good than harm at reasonable cost.
The efficacy of herbal medicines has been tested in
hundreds of clinical trials, and it is wrong to say that they
are all of inferior methodological quality. But this
volume of data is still small considering the multitude of
herbal medicines—worldwide several thousand different
plants are being used for medicinal purposes.4 A recent
overview included 23 systematic reviews of rigorous
trials of herbal medicines.5 Eleven came to a positive
conclusion, nine yielded promising but not convincing
results, and three were negative. The relative paucity of
rigorous clinical trials is mostly due to the fact that, com-
pared with the pharmaceutical sector, the herbal indus-
try is small and can rarely afford the considerable
expense of a clinical trial. Sadly the traditional use direc-
tive, which sets out to harmonise the registration of
herbal medicines in the European Union,6 lacks any
incentive for companies to invest further into research.
Public funds are only very rarely dedicated to research in
this area.7
Even though herbal medicines are not devoid of
risk,1 they could still be safer than synthetic drugs.
Between 1968 and 1997, the World Health Organiza-
tion’s monitoring centre collected 8985 reports of
adverse events associated with herbal medicines from 55
countries.8 Although this number may seem impres-
sively high, it amounts to only a tiny fraction of adverse
events associated with conventional drugs held in the
same database.8 However, the relative paucity could also
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